The estimated Net Worth of Anja B Krammer is at least $5.84 Million dollars as of 23 January 2019. Anja Krammer owns over 115,874 units of Vivos Therapeutics stock worth over $5,727,743 and over the last 8 years Anja sold VVOS stock worth over $107,746.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Anja Krammer VVOS stock SEC Form 4 insiders trading
Anja has made over 2 trades of the Vivos Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Anja sold 115,874 units of VVOS stock worth $12,746 on 23 January 2019.
The largest trade Anja's ever made was selling 500,000 units of Vivos Therapeutics stock on 10 October 2018 worth over $95,000. On average, Anja trades about 51,323 units every 9 days since 2016. As of 23 January 2019 Anja still owns at least 1,884,126 units of Vivos Therapeutics stock.
You can see the complete history of Anja Krammer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Anja Krammer's mailing address?
Anja's mailing address filed with the SEC is 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON, CO, 80120.
Insiders trading at Vivos Therapeutics
Over the last 4 years, insiders at Vivos Therapeutics have traded over $0 worth of Vivos Therapeutics stock and bought 88,521 units worth $136,211 . The most active insiders traders include Anja B Krammer, Ronald Kirk Huntsman, and Bradford K. Amman. On average, Vivos Therapeutics executives and independent directors trade stock every 77 days with the average trade being worth of $22,426. The most recent stock trade was executed by Ronald Kirk Huntsman on 20 June 2023, trading 14,000 units of VVOS stock currently worth $7,420.
What does Vivos Therapeutics do?
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
What does Vivos Therapeutics's logo look like?
Complete history of Anja Krammer stock trades at BioPharmX and Vivos Therapeutics
Vivos Therapeutics executives and stock owners
Vivos Therapeutics executives and other stock owners filed with the SEC include:
-
R. Kirk Huntsman,
Co-Founder, Chairman & CEO -
Dr. Gurdev Dave Singh D.M.D., Ph.D.,
Founder, Chief Medical Officer & Director -
Bradford K. Amman,
CFO, Treasurer & Sec. -
Ruth Hembree,
Sr. VP -
Nicholas M. DeGennaro,
Sr. VP of the Medical Integration Division -
David Bryan Ferre,
Sr. VP of Marketing -
Cathryn H. Bonar,
Chief Compliance Officer and Sr. VP of Compliance & Medical Billing -
Edward A. Loew,
Chief Strategy Officer, Sr. VP of Strategy & Investor Relations Officer -
Susan McCullough,
Co-Founder & Sr. VP of Operations -
RaeAnn Byrnes,
Co-Founder and Sr. VP of People, Training & Devel. -
Todd Huntsman,
Co-Founder & Sr. VP of Manufacturing -
Bradford K. Amman,
Chief Financial Officer -
Leonard J Sokolow,
Director -
Anja B Krammer,
Director -
Ralph Elias Green,
Director -
Mark F. Lindsay,
Director -
Gurdev Dave Singh,
Chief Medical Officer -
Matthew Thompson,
Director -
Ronald Kirk Huntsman,
Chief Executive Officer